Bendamustine and Ofatumumab for Waldenström’s

Waldenström's macroglobulinemia (WM) is a disease which produces CD20 antibodies  and which corresponds to a pathological diagnosis of IgM secreting lymphoplasmacytic lymphoma. Since 1999, there have been many reports and several phase II studies of Rituxan in this disease. Major response rates of 30% have been reported in most studies with standard dose rituximab, i.e. 4 weekly infusions at 375 mg/m2/week.  A recent guideline states: "Rituximab

Read more